Updated from 7:42 a.m. EDTEli Lilly ( LLY) released third-quarter earnings that beat Wall Street estimates even as its best-selling product continued to slip in the U.S. market. Lilly also issued fourth-quarter and full-year earnings guidance that's within the range of financial analysts' consensus estimates. Lately, Lilly's stock was off 34 cents to $51.26. The profit for the three months ended Sept. 30 rose to $794.4 million, or 73 cents a share, from $755.2 million, or 69 cents a share, last year. Sales rose 10% from the year-ago period to $3.60 billion, Lilly said Thursday. On average, analysts had been forecasting earnings of 71 cents a share in the latest quarter on sales of $3.62 billion. For the fourth quarter, Lilly put earnings at 73 cents to 79 cents a share, excluding one-time items, compared with the Thomson First Call consensus estimate of 76 cents a share. Lilly predicted full-year earnings of $2.80 to $2.86, excluding special items. The consensus is $2.82. If items are included, the Indianapolis-based drugmaker says full-year earnings will be $1.90 to $1.96. The company had a "decent quarter," says Tim Anderson of Prudential Equity Group in a research note, even though sales fell below his $3.7 billion prediction. He maintains his neutral rating. He doesn't own shares, and his firm doesn't have an investment banking relationship. "Major products were roughly in line with our view," says James Kelly of Goldman Sachs. Kelly adds that he's concerned about "prescription weakness" in several big products. Kelly has a neutral rating on the stock. He doesn't own shares, but his firm has had a recent investment banking relationship with Lilly. One product on Kelly's worry list is the schizophrenia drug Zyprexa, which accounted for 29% of Lilly's third-quarter revenue. U.S. sales declined 10%, but foreign-market sales rose 14%, giving Zyprexa a worldwide sales gain of 1% to $1.04 billion.